ey0020.6-6 | Clinical Trials – New Treatments | ESPEYB20
Newfield Ron S
, Sarafoglou Kyriakie
, Fechner Patricia Y
, Nokoff Natalie J
, Auchus Richard J
, Vogiatzi Maria G
, Jeha George S
, Giri Nagdeep
, Roberts Eiry
, Sturgeon Julia
, Chan Jean L
, Farber Robert H
Brief summary: This study evaluated the safety, tolerability and efficacy of Crinecerfont, a CRF1R antagonist in adolescents with classic congenital adrenal hyperplasia (CAH).Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is characterized by impaired cortisol synthesis and excess adrenal androgen secretion. Sufficient suppression of adrenal andogen production in classic CAH may be difficult with current formulations...